Horizon Therapeutics

$94.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.89 (+3.14%) As of 8:56 PM UTC today

Why Robinhood?

You can buy or sell HZNP and other stocks, options, and ETFs commission-free!

About HZNP

Horizon Therapeutics Public Limited Company Ordinary Shares, also called Horizon Therapeutics, is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. The listed name for HZNP is Horizon Therapeutics Public Limited Company Ordinary Shares.

CEO
Timothy P. Walbert
Employees
1,200
Headquarters
Dublin, Dublin
Founded
2008
Market Cap
22.23B
Price-Earnings Ratio
50.22
Dividend Yield
—
Average Volume
2.28M
High Today
$95.49
Low Today
$90.89
Open Price
$92.52
Volume
1.85M
52 Week High
$96.54
52 Week Low
$23.81

HZNP Earnings

$0.21
$0.72
$1.23
$1.74
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
$1.05 per share
Actual
$1.28 per share
Replay Earnings Call

You May Also Like

AAA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure